Cover Image

Cost-effectiveness of nonavalent HPV vaccination in the Netherlands

ABSTRACTBackground A bivalent human papillomavirus vaccine (2vHPV) is currently used in the Netherlands; a nonavalent vaccine (9vHPV) is also licensed.Research design and methods We compared the public health and economic benefits of 2vHPV- and 9vHPV-based vaccination strategies in the Netherlands o...

Full description

Saved in:

Bibliographic Details
Main Authors:	Cody Palmer (Author), Christiaan Dolk (Author), Ugne Sabale (Author), Wei Wang (Author), Kunal Saxena (Author)
Format:	Book
Published:	Taylor & Francis Group, 2024-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain
by: Jesús De La Fuente, et al.
Published: (2019)

9vHPV (Nonavalent) Vaccine Policy in Indonesia
by: Yudi M. Hidayat, et al.
Published: (2023)

Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine
by: Karl-Ulrich Petry, et al.
Published: (2018)

Concurrent nonavalent human papillomavirus (HPV) vaccination and immune stimulation with imiquimod to treat recalcitrant HPV-associated high grade vaginal intra-epithelial neoplasia
by: R. Farrell, et al.
Published: (2024)

Estimating the time required to reach HPV vaccination targets across Europe
by: Ilias Gountas, et al.
Published: (2024)

Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: A referral hospital-based study in Sicily
by: Giuseppina Capra, et al.
Published: (2017)

Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later - an exploratory study
by: Vladimir Gilca, et al.
Published: (2019)

Nonavalent human papillomavirus vaccination as a treatment for warts in an immunosuppressed adult
by: Sara B. Ferguson, MD, et al.
Published: (2017)

Childhood erythrodermic lichen planus pemphigoides after nonavalent human papillomavirus vaccination
by: Laura Pizzatti, MD, et al.
Published: (2020)

Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis
by: Kate T Simms, DrPhD, et al.
Published: (2016)

Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong
by: Tak Hong Cheung, et al.
Published: (2023)

Nonavalent Human Papillomavirus Vaccination as a Treatment for Skin Warts in Immunosuppressed Adults: A Case Series
by: Simon Bossart, et al.
Published: (2020)

Public health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals through age 45 years in the United States
by: Vincent Daniels, et al.
Published: (2021)

Determinants of HPV-vaccination uptake and subgroups with a lower uptake in the Netherlands
by: A. C. de Munter, et al.
Published: (2021)

Ten years of HPV vaccination in the Netherlands: current evidence and future challenges in HPV-related disease prevention
by: V. Qendri, et al.
Published: (2018)

Estimating the lifetime cost of vaccination in 23 European Countries: a modeling study
by: Goran Bencina, et al.
Published: (2023)

Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model
by: Hak Eelko, et al.
Published: (2011)

To vaccinate or not to vaccinate? Perspectives on HPV vaccination among girls, boys, and parents in the Netherlands: a Q-methodological study
by: Nathalie J. S. Patty, et al.
Published: (2017)

Updated medical care cost estimates for HPV-associated cancers: implications for cost-effectiveness analyses of HPV vaccination in the United States
by: Harrell W. Chesson, et al.
Published: (2019)

Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands
by: van Lier Alies, et al.
Published: (2010)

Analysis of the Economic and Socio-Demographic Burden of HPV-Associated Diseases and the Cost-Effectiveness of HPV Vaccination in Russia
by: Alexander A. Baranov, et al.
Published: (2019)

Cost-effectiveness and epidemiological impact of gender-neutral HPV vaccination in Spain
by: Renata Linertová, et al.
Published: (2022)

Health-care costing in the Netherlands
by: Rutgers H, et al.
Published: (2010)

Implementation strategy and cost of Mozambique's HPV vaccine demonstration project
by: Caroline Soi, et al.
Published: (2019)

Cost-effectiveness of human papillomavirus (HPV) vaccination in Burkina Faso: a modelling study
by: Joël Arthur Kiendrébéogo, et al.
Published: (2023)

Cost-effectiveness of prucalopride in the treatment of chronic constipation in the Netherlands
by: Mark J C Nuijten, et al.
Published: (2015)

A longitudinal study on determinants of HPV vaccination uptake in parents/guardians from different ethnic backgrounds in Amsterdam, the Netherlands
by: Catharina J. Alberts, et al.
Published: (2017)

Disparities in healthcare access and utilization and human papillomavirus (HPV) vaccine initiation in the United States
by: Kunal Goel, et al.
Published: (2021)

Costs in the Last Year of Life in the Netherlands
by: Tom Stooker, et al.
Published: (2001)

Assessing the long-term implications of age 9 initiation of HPV vaccination on series completion by age 13-15 in the US: projections from an age-structured vaccination model
by: Kunal Saxena, et al.
Published: (2024)

Association of provider HPV vaccination training with provider assessment of HPV vaccination status and recommendation of HPV vaccination
by: Ikponmwosa Osaghae, et al.
Published: (2022)

HPV vaccine initiation at 9 or 10 years of age and better series completion by age 13 among privately and publicly insured children in the US
by: Kunal Saxena, et al.
Published: (2023)

HPV-Vaccines
Published: (2023)

Cost- effectiveness of HPV vaccination regime: comparing twice versus thrice vaccinations dose regime among adolescent girls in Malaysia
by: Syed Aljunid, et al.
Published: (2016)

Cost-effectiveness in extracorporeal life support in critically ill adults in the Netherlands
by: Annemieke Oude Lansink-Hartgring, et al.
Published: (2018)

Decline in HPV-vaccination uptake in Denmark - the association between HPV-related media coverage and HPV-vaccination
by: Camilla Hiul Suppli, et al.
Published: (2018)

Cost-effectiveness of sensor-augmented insulin pump therapy vs continuous subcutaneous insulin infusion in patients with type 1 diabetes in the Netherlands
by: Roze S, et al.
Published: (2019)

Cost-effectiveness of Human Papilloma Virus (HPV) vaccination in Nigeria: a decision analysis using pragmatic parameter estimates for cost and programme coverage
by: Obinna I. Ekwunife, et al.
Published: (2017)

Clinical performance of high-risk HPV testing on self-samples versus clinician samples in routine primary HPV screening in the Netherlands: An observational study
by: Federica Inturrisi, et al.
Published: (2021)

Evaluation of an HPV vaccine toolkit to improve OB/GYN discussion of HPV vaccination
by: Sarah Simko, et al.
Published: (2024)